New Jersey A3117 requires health insurance coverage for BRCA1 and BRCA2 gene testing.
New Jersey A3117 mandates that health insurance policies and contracts cover testing for BRCA1 and BRCA2 genes, which are linked to breast cancer. The bill applies to various types of health insurance policies and contracts, including those issued by hospital service corporations, health service corporations, medical service corporations, and group policies. A positive test result for BRCA1 or BRCA2 qualifies as "positive genetic testing" for breast cancer, allowing for additional testing.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.